An Open-Label, Randomized, Controlled Phase-II Trial Evaluating the Efficacy and Safety of EndoTAG-1 in Triple Receptor Negative Breast Cancer Patients.
Phase of Trial: Phase II
Latest Information Update: 01 Apr 2014
At a glance
- Drugs Paclitaxel (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- Sponsors MediGene AG
- 01 Apr 2014 Results published in the Annals of Oncology.
- 04 Jan 2012 Actual end date Mar 2011 added as reported by ClinicalTrials.gov.
- 09 Dec 2011 Results presented at the 34th Annual San Antonio Breast Cancer Symposium, according to a MediGene media release.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History